Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice

Carcinogenesis

Volumn 24, Issue 3, 2003, Pages 461-467

  Ramos Gomez, Minerva ^a,c   Dolan, Patrick M ^a   Itoh, Ken ^b   Yamamoto, Masayuki ^b   Kensler, Thomas W ^a  

^a Johns Hopkins University   (United States)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSIDAD AUTÓNOMA DE QUERÉTARO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; CYTOCHROME P450; DRUG VEHICLE; OLTIPRAZ; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ADDUCT; DNA ISOLATION; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; FORESTOMACH; GENE DISRUPTION; GENE FUNCTION; GENOTYPE; LIVER; LIVER LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE; TUMOR VOLUME; WILD TYPE;

ANIMALS; ANTICARCINOGENIC AGENTS; BENZO(A)PYRENE; DNA ADDUCTS; DNA-BINDING PROTEINS; GENOTYPE; MICE; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; PYRAZINES; TRANS-ACTIVATORS;

EID: 0037356451     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/24.3.461     Document Type: Review

References (45)

1. Wattenberg,L.W. and Bueding,E. (1986) Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard. Carcinogenesis, 7, 1379-1381.
2. Kensler,T.W. and Helzlsouer,K.J. (1995) Oltipraz: clinical opportunities for cancer chemoprevention. J. Cell. Biochem. Suppl., 22, 101-107.
3. Benson,A.B., 3rd (1993) Oltipraz: a laboratory and clinical review. J. Cell. Biochem. Suppl., 17: 278-291.
4. De Long,M.J., Prochaska,H.J. and Talalay,P. (1986) Induction of NAD (P)H:quinone reductase in murine hepatoma cells by phenolic antioxidants, azo dyes and other chemoprotectors: a model system for the study of anticarcinogens. Proc. Natl Acad. Sci. USA, 83, 787-791.
5. Clapper,M.L. (1998) Chemopreventive activity of oltipraz. Pharmacol. Ther., 78, 17-27.
6. Egner,P.A., Gange,S.J., Dolan,P.M., Groopman,J.D., Munoz,A. and Kensler,T.W. (1995) Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis, 16, 1769-1773.
7. Rushmore,T.H., Morton,M.R. and Pickett,C.B. (1991) The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem., 266, 11632-11639.
8. Prestera,T., Zhang,Y., Spencer,S.R., Wilczak,C.A. and Talalay,P. (1993) The electrophile counterattack response: protection against neoplasia and toxicity. Adv. Enzyme Regul., 33, 281-296.
9. Wasserman,W.W. and Fahl,W.E. (1997) Functional antioxidant responsive elements. Proc. Natl Acad. Sci. USA, 94, 5361-5366.
10. Venugopal,R. and Jaiswal,A.K. (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD (P)H:quinone oxidoreductase1 gene. Proc. Natl Acad. Sci. USA, 93, 14960-14965.
11. Itoh,K., Chiba,T., Takahashi,S. et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun., 236, 313-322.
12. Moi,P., Chan,K., Asunis,I., Cao,A. and Kan,Y.W. (1994) Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl Acad. Sci. USA, 91, 9926-9930.
13. Marini,M.G., Chan,K., Casula,L., Kan,Y.W., Cao,A. and Moi,P. (1997) hMAF, a small human transcription factor that heterodimerizes specifically with Nrf1 and Nrf2. J. Biol. Chem., 272, 16490-16497.
14. Nguyen,T., Huang,H.C. and Pickett,C.B. (2000) Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J. Biol. Chem., 275, 15466-15473.
15. Chan,K., Lu,R., Chang,J.C. and Kan,Y.W. (1996) NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth and development. Proc. Natl Acad. Sci. USA, 93, 13943-13948.
16. Chan,J.Y. and Kwong,M. (2000) Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim. Biophys. Acta, 1517, 19-26.
17. Hayes,J.D., Chanas,S.A., Henderson,C.J., McMahon,M., Sun,C., Moffat,G.J., Wolf,C.R. and Yamamoto,M. (2000) The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem. Soc. Trans., 28, 33-41.
18. McMahon,M., Itoh,K., Yamamoto,M., Chanas,S.A., Henderson,C.J., McLellan,L.I., Wolf,C.R., Cavin,C. and Hayes,J.D. (2001) The Cap 'n' Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res., 61, 3299-3307.
19. Chanas,S.A., Jiang,Q., McMahon,M. et al. (2002) Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem. J., 365, 405-416.
20. Chan,K. and Kan,Y.W. (1999) Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl Acad. Sci. USA, 96, 12731-12736.
21. Cho,H.Y., Jedlicka,A.E., Reddy,S.P., Kensler,T.W., Yamamoto,M., Zhang,L.Y. and Kleeberger,S.R. (2002) Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell Mol. Biol., 26, 175-182.
22. Aoki,Y., Sato,H., Nishimura,N., Takahashi,S., Itoh,K. and Yamamoto,M. (2001) Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol. Appl. Pharmacol., 173, 154-160.
23. Chan,K., Han,X.D. and Kan,Y.W. (2001) An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl Acad. Sci. USA, 98, 4611-4616.
24. Enomoto,A., Itoh,K., Nagayoshi,E., Haruta,J., Kimura,T., O'Connor,T., Harada,T. and Yamamoto,M. (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci., 59, 169-177.
25. Braun,S., Hanselmann,C., Gassmann,M.G., auf dem Keller,U., Born-Berclaz,C., Chan,K., Kan,Y.W. and Werner,S. (2002) Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell. Biol., 22, 5492-5505.
26. Ramos-Gomez,M., Kwak,M.K., Dolan,P.M., Itoh,K., Yamamoto,M., Talalay,P. and Kensler,T.W. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl Acad Sci. USA, 98, 3410-3415.
27. Fahey,J.W., Haristoy,X., Dolan,P.M., Kensler,T.W., Scholtus,I., Stephenson,K.K., Talalay,P. and Lozniewski,A. (2002) Sulforaphane inhibits extracellular, intracellular and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl Acad. Sci. USA, 99, 7610-7615.
28. Langouet,S., Maheo,K., Berthou,F., Morel,F., Lagadic-Gossman,D., Glaise,D., Coles,B., Ketterer,B. and Guillouzo,A. (1997) Effects of administration of the chemoprotective agent oltipraz on CYP1A and CYP2B in rat liver and rat hepatocytes in culture. Carcinogenesis, 18, 1343-1349.
29. Langouet,S., Furge,L.L., Kerriguy,N., Nakamura,K., Guillouzo,A. and Guengerich,F.P. (2000) Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives and sulforaphane. Chem. Res. Toxicol., 13, 245-252.
30. Sofowora,G.G., Choo,E.F., Mayo,G., Shyr,Y. and Wilkinson,G.R. (2001) In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother. Pharmacol., 47, 505-510.
31. Le Ferrec,E., Ilyin,G., Maheo,K., Bardiau,C., Courtois,A., Guillouzo,A. and Morel,F. (2001) Differential effects of oltipraz on CYP1A and CYP2B in rat lung. Carcinogenesis, 22, 49-55.
32. Wattenberg,L.W. (1977) Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J. Natl Cancer Inst., 58, 395-398.
33. Alexandrov,K., Rojas,M., Geneste,O., Castegnaro,M., Camus,A.M., Petruzzelli,S., Giuntini,C. and Bartsch,H. (1992) An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res., 52, 6248-6253.
34. Sticha,K.R., Staretz,M.E., Wang,M., Liang,H., Kenney,P.M. and Hecht,S.S. (2000) Effects of benzyl isothiocyanate and phenethyl isothiocyanate on benzo[a]pyrene metabolism and DNA adduct formation in the A/J mouse. Carcinogenesis, 21, 1711-1719.
35. Herron,D.C. and Shank,R.C. (1982) DNA methylation during chronic administration of 1,2-dimethylhydrazine in a carcinogenic regimen. Carcinogenesis, 3, 857-860.
36. Bauer,E., Guo,Z., Ueng,Y.F, Bell,L.C., Zeldin,D. and Guengerich,F.P. (1995) Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol., 8, 136-142.
37. Kim,J.H., Stansbury,K.H., Walker,N.J., Trush,M.A., Strickland,P.T. and Sutter,T.R. (1998) Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis, 19, 1847-1853.
38. Shimada,T., Oda,Y., Gillam,E.M., Guengerich,F.P. and Inoue,K. (2001) Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab. Dispos., 29, 1176-1182.
39. Buetler,T.M., Gallagher,E.P., Wang,C., Stahl,D.L., Hayes,J.D. and Eaton,D.L. (1995) Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein and activity by BHA, ethoxyquin and oltipraz. Toxicol. Appl. Pharmacol., 135, 45-57.
40. Murray,G.I. (2000) The role of cytochrome P450 in tumour development and progression and its potential in therapy. J. Pathol., 192, 419-426.
41. Dey,A., Jones,J.E. and Nebert,D.W. (1999) Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. Biochem. Pharmacol., 58, 525-537.
42. Thapliyal,R., Deshpande,S.S. and Maru,G.B. (2002) Mechanism(s) of turmeric-mediated protective effects against benzo(a)pyrene-derived DNA adducts. Cancer Lett., 175, 79-88.
43. Ryu,D.Y. and Hodgson,E. (1999) Constitutive expression and induction of CYP1B1 mRNA in the mouse. J. Biochem. Mol. Toxicol., 13, 249-251.
44. Shimada,T. Inoue,K., Suzuki,Y. et al. (2002) Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis, 23, 1199-1207.
45. Kensler,T.W., Groopman,J.D., Sutter.T.R., Curphey,T.J. and Roebuck,B.D. (1999) Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem. Res. Toxicol., 12, 113-126